Personalized Medicine Portfolio
This collection features innovative companies revolutionizing healthcare by developing treatments tailored to individual genetic profiles. Carefully selected by our analysts, these stocks represent the cutting edge of precision medicine, where customized therapies aim to deliver more effective patient outcomes.
Your Basket's Financial Footprint
Aggregate market capitalisation and investor takeaways for the provided basket.
- Large-cap dominance generally implies lower volatility and closer broad-market tracking, reducing idiosyncratic risk.
- Suitable as a core, long-term holding for diversification rather than a short-term speculative position.
- Expect steady, long-term value creation rather than rapid, short-term gains; growth may be more measured.
PSNL: $848.64M
PRME: $977.47M
EDIT: $348.89M
- Other
About This Group of Stocks
Our Expert Thinking
The healthcare industry is shifting from one-size-fits-all treatments to therapies designed for specific genetic profiles. Companies in this collection are pioneering technologies that target diseases at their molecular source, potentially offering more effective treatments with fewer side effects.
What You Need to Know
This portfolio includes companies at various stages of innovation—from diagnostic tools to therapeutic development. Consider this an aggressive growth component for your investments, as many firms are still developing commercial pathways for their technologies.
Why These Stocks
These companies were selected for their leadership in genomic sequencing, biomarker discovery, and targeted therapies like CRISPR gene editing. Recent regulatory approvals for gene-specific treatments and AI advancements in drug discovery provide significant growth catalysts.
Why You'll Want to Watch These Stocks
The DNA of Future Medicine
Personalized medicine is rewriting healthcare's rulebook. These companies are at the forefront of a revolution that could make traditional treatments obsolete while creating entirely new markets.
Breakthrough Momentum
Recent regulatory approvals for gene therapies are accelerating the path to market. As more personalized treatments gain validation, these pioneering companies could see rapid adoption and growth.
Beyond One-Size-Fits-All
Imagine treatments designed specifically for your genetic code. These companies are making this a reality, potentially capturing massive value as healthcare shifts toward precision therapies with better outcomes.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Digital Trust Stocks | Cybersecurity Investment Opportunity
Fifteen global tech giants, led by Microsoft and Ericsson, have formed an alliance to establish a common framework for digital trust and security. This move signals a growing demand for specialized cybersecurity and verification technologies, creating an investment opportunity in companies that provide the essential tools for a trusted digital ecosystem.
Food Safety Stocks: What's Next After Costco Lawsuit
A recent lawsuit against Costco regarding salmonella in its rotisserie chicken has intensified focus on food safety across the grocery industry. This creates a potential investment opportunity in companies that provide testing, diagnostics, and supply chain verification services.
Founder-Controlled Stocks May Gain Focus in 2025
SpaceX is reportedly considering a dual-class share structure for its IPO to ensure founder Elon Musk retains control. This move could spark investor interest in other public companies where founders or insiders hold significant voting power through similar stock structures.